
Find Reports
Select Report Type
Reimbursement Review
Displaying 176 - 200 of 1264
Please scroll or swipe to the right to view the full content.
Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
---|---|---|---|---|---|---|---|---|
Livtencity | maribavir | Post-transplant cytomegalovirus infection | Reimburse with clinical criteria and/or conditions | Complete | SR0720-000 | |||
Rozlytrek | entrectinib | Extracranial solid tumours with NTRK gene fusion | Reimburse with clinical criteria and/or conditions | Complete | PC0278-000 | |||
Cabometyx | cabozantinib | Differentiated thyroid carcinoma | Reimburse with clinical criteria and/or conditions | Complete | PC0287-000 | |||
Jardiance | empagliflozin | Heart failure | Reimburse with clinical criteria and/or conditions | Complete | SR0726-000 | |||
Vabysmo | faricimab | Diabetic Macular Edema | Reimburse with clinical criteria and/or conditions | Complete | SR0729-000 | |||
Gavreto | pralsetinib | RET fusion-positive non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0283-000 | |||
Verzenio | abemaciclib | Adjuvant treatment of HR-positive, HER2-negative early breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0282-000 | |||
Keytruda | pembrolizumab | Renal cell carcinoma, adjuvant | Reimburse with clinical criteria and/or conditions | Complete | PC0273-000 | |||
Minjuvi | tafasitamab | Diffuse large B-cell lymphoma (DLBCL) | Do not reimburse | Complete | PC0266-000 | |||
Lutathera | lutetium oxodotreotide | Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) | Reimburse with clinical criteria and/or conditions | Complete | PC0284-000 | |||
Enhertu | trastuzumab deruxtecan | Metastatic HER2 positive breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0285-000 | |||
Opdivo | nivolumab | Urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Complete | PC0272-000 | |||
Retevmo | selpercatinib | Thyroid cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0264-000 | |||
Wegovy | semaglutide | Weight management | Do not reimburse | Complete | SR0725-000 | |||
Jakavi | ruxolitinib | Graft versus host disease | Reimburse with clinical criteria and/or conditions | Complete | SR0688-000 | |||
Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0288-000 | |||
Tecentriq | atezolizumab | Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0277-000 | |||
Tecentriq | atezolizumab | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0269-000 | |||
Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0279-000 | |||
Jemperli | dostarlimab | Endometrial cancer | Do not reimburse | Complete | PC0263-000 | |||
Tepmetko | tepotinib | Locally advanced or metastatic non-small cell lung cancer | Do not reimburse | Complete | PC0255-000 | |||
Cibinqo | abrocitinib | Atopic dermatitis, moderate to severe | Reimburse with clinical criteria and/or conditions | Complete | SR0686-000 | |||
Vabysmo | faricimab | Macular degeneration, age-related | Reimburse with clinical criteria and/or conditions | Complete | SR0719-000 | |||
Poteligeo | mogamulizumab | mycosis fungoides (MF), Sézary syndrome (SS) | Reimburse with clinical criteria and/or conditions | Complete | PC0244-000 | |||
Spinraza | nusinersen | Spinal Muscular Atrophy | Do not reimburse | Complete | SR0713-000 |
Health Technology Review
Displaying 176 - 200 of 590
Please scroll or swipe to the right to view the full content.
Horizon Scan
Displaying 101 - 111 of 111
Projects in Progress
Displaying 26 - 39 of 39
View All Reports
Displaying 176 - 200 of 2100
Please scroll or swipe to the right to view the full content.
Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
---|---|---|---|---|---|---|---|
HR positive, HER2 negative breast cancer | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0053-000 | |||
Environmental Scan of Genetic and Genomic Biomarker Testing Assessment Frameworks, Processes, and Inventories in Cancer Care | Health Technology Review | In Progress | CP0037-000 | ||||
etrasimod | Reimbursement Review | Complete | SR0795-000 | ||||
naloxagol | Reimbursement Review | Active | SX0753-000 | ||||
burosumab | Reimbursement Review | Active | SR0818-000 | ||||
Use of Oral Fluoroquinolones in Canada: Drug Utilization Study Update | Health Technology Review | Technology Review | Complete | HC0073-000 | |||
Mepolizumab | Reimbursement Review | Complete | SX0839-000 | ||||
Non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0054-000 | |||
Artificial Intelligence–Assisted Colonoscopy for Detecting Polyps, Adenomas, Precancerous Lesions, and Colorectal Cancer | Health Technology Review | Rapid Review | Completed | RC1559-000 | |||
RapidAI for Stroke Detection | Health Technology Review | Optimal Use | Active | OP0556-000 | |||
Advanced or metastatic gastric, gastroesophageal junction, or esophageal cancer | Reimbursement Review | Provisional Funding Algorithm | Complete | PH0051-000 | |||
Appropriate Use of Antipsychotics in Long-Term Care | Health Technology Review | Technology Review | Active | HC0095-000 | |||
Attention-Deficit/Hyperactivity Disorder Medications for Adults | Health Technology Review | Rapid Review | Completed | RC1556-000 | |||
Pharmaceutical Reviews Update — Issue 53 | Reimbursement Review | Pharmaceutical Review Update | |||||
Esophageal or Gastroesophageal Junction Cancer | Reimbursement Review | Provisional Funding Algorithm | Active | PH0061-000 | |||
Multiple Myeloma | Reimbursement Review | Provisional Funding Algorithm | Active | PH0060-000 | |||
NSCLC without actionable oncogenic alterations | Reimbursement Review | Provisional Funding Algorithm | Active | PH0059-000 | |||
Overview of Systematic Reviews of Immune Checkpoint Inhibitors in Non–Small-Cell Lung Cancer with EGFR, ALK, ROS1, and RET Actionable Driver Mutations | Health Technology Review | Systematic Review | Completed | RE0050-000 | |||
Utilization of Cancer Therapies for Advanced Non–Small Cell Lung Cancer With an Oncogenic Driver Mutation | Health Technology Review | Technology Review | Completed | HC0084-OS0008 | |||
Enzalutamide | Reimbursement Review | Complete | PX0366-000 | ||||
remdesivir | Reimbursement Review | Complete | SR0834-000 | ||||
ciltacabtagene autoleucel | Reimbursement Review | Active | PG0361-000 | ||||
ruxolitinib | Reimbursement Review | Active | SR0835-000 | ||||
Benchmarking CT and MRI exams | Health Technology Review | In Progress | CM0016-000 | ||||
Virtual remote CT and MRI | Health Technology Review | In Progress | CM0017-000 |